Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mehow InnovativeSZSE:301363 -0.62%93 ROE % is 7.24% as of Jun. 2026, which is 66% below its 10-year median of 21.21. GuruFocus rates SZSE:301363 with a GF Score™ of 93/100 and a GF Value™ of ¥20.50 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Mehow Innovative ranks better than 64.87% on this metric.
The historical rank and industry rank for Mehow Innovative's ROE % or its related term are showing as below:
SZSE:301363'
s ROE % Range Over the Past 10 Years
Min: 7.85 Med: 21.21 Max: 31.73
Current: 7.92
During the past 8 years, Mehow Innovative's highest ROE % was 31.73%. The lowest was 7.85%. And the median was 21.21%.
SZSE:301363's ROE % is ranked better than 64.87% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 2.75
vs SZSE:301363: 7.92
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Mehow Innovative ROE % Related Terms
Mehow Innovative ROE % Historical Data
* Premium members only.
The historical data trend for Mehow Innovative's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Mehow Innovative's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mehow Innovative ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mehow Innovative's ROE % distribution charts can be found below:
* The bar in red indicates where Mehow Innovative's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Mehow Innovative (SZSE:301363) has a ROE % of 7.24% as of Jun. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Mehow Innovative and its competitors. This is 66% below median its historical median of 21.21. Over the past decade, Mehow Innovative's ROE % has ranged from 7.85 to 31.73. According to the industry distribution chart, Mehow Innovative ranks #280 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 35.1%.
Is Mehow Innovative's ROE % too high?
Mehow Innovative's current ROE % of 7.24% is 66% below median its 10-year median of 21.21. Over the past 10 years, this metric has ranged from a low of 7.85 to a high of 31.73. The Medical Devices & Instruments industry median ROE % is 2.75. Mehow Innovative's value of 7.24% is 163.3% above this industry median. Based on the distribution chart, Mehow Innovative ranks #280 out of 797 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Mehow Innovative has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mehow Innovative's ROE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mehow Innovative ranks #280 out of 797 companies for ROE %. This puts Mehow Innovative in the upper half of its industry. The industry median ROE % is 2.75. Mehow Innovative's value of 7.24% is 163.3% above this benchmark. Historically, Mehow Innovative's own ROE % has ranged from 7.85 to 31.73 over the past decade. While the company's 10-year median is 21.21 vs. the industry median of 2.75, Mehow Innovative has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.75, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mehow Innovative's current ROE % of 7.24% is 163.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Mehow Innovative and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mehow Innovative's current ROE % is 7.24%, which is 66% below median its own 10-year median of 21.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mehow Innovative stock overvalued right now?
Based on GuruFocus' analysis, Mehow Innovative (SZSE:301363) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥20.50, compared to a current price of ¥16.03 — trading 21.8% below its estimated fair value. The current ROE % is 7.24%, which is 66% below median its 10-year median of 21.21 and 163.3% above the Medical Devices & Instruments industry median of 2.75. Mehow Innovative's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Mehow Innovative (SZSE:301363), the current ROE % is 7.24% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mehow Innovative (SZSE:301363) Overvalued in 2026?
Based on GuruFocus' analysis, Mehow Innovative stock appears to be undervalued.
The current stock price of ¥16.03 is trading 21.8% below its estimated GF Value™ of ¥20.50.
GuruFocus considers Mehow Innovative to be Modestly Undervalued.
Key valuation signals for SZSE:301363:
ROE %: 7.24% (66% below median its 10-year median of 21.21)
GF Value™: ¥20.50 vs. price of ¥16.03 (21.8% below fair value)
Industry Position: 163.3% above the Medical Devices & Instruments median (#280 of 797)
No single metric tells the full story. See the SZSE:301363 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:301363 has been successfully added to your 
